(Total Views: 302)
Posted On: 02/09/2021 10:20:50 AM
Post# of 36542
This is the thing that most concerns me about the American market for GNBT/NGIO vaccine. Joe mentioned in the CC about long term immunity in Pfizer and Moderna. But the publication from the July Phase I,II T-Cell response seems to indicate Pfizer illicits long term memory cells. Moderna less so ... which Joe mentioned Moderna now giving 3rd shots to trial participants ... maybe suggesting Moderna does not provide long term immunity.
"Pfizer and BioNTech have shared (PDF) phase 1/2 data suggesting their COVID-19 vaccine triggers stronger CD8 T-cell responses than Moderna’s rival candidate. Four-fifths of subjects who received BNT162b1 had vaccine-induced CD8 T-cell responses and researchers classed most of the responses as strong."
https://www.fiercebiotech.com/biotech/pfizer-...19-vaccine
actual report:
https://www.medrxiv.org/content/10.1101/2020....1.full.pdf
"Pfizer and BioNTech have shared (PDF) phase 1/2 data suggesting their COVID-19 vaccine triggers stronger CD8 T-cell responses than Moderna’s rival candidate. Four-fifths of subjects who received BNT162b1 had vaccine-induced CD8 T-cell responses and researchers classed most of the responses as strong."
https://www.fiercebiotech.com/biotech/pfizer-...19-vaccine
actual report:
https://www.medrxiv.org/content/10.1101/2020....1.full.pdf
(0)
(0)
Scroll down for more posts ▼